anmelden
OMX Nordic 40
2.707,95
PKT
-0,48
PKT
-0,02
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Nordic 40-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 13.01.26 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 13.01.26 | Volvo (B) Outperform | RBC Capital Markets | |
| 13.01.26 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 13.01.26 | Nokia Buy | Jefferies & Company Inc. | |
| 12.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 12.01.26 | Hennes Mauritz (H M, H&M) Underperform | Bernstein Research | |
| 08.01.26 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 08.01.26 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 08.01.26 | Volvo (B) Buy | Goldman Sachs Group Inc. | |
| 07.01.26 | Volvo (B) Market-Perform | Bernstein Research | |
| 07.01.26 | Novo Nordisk Equal Weight | Barclays Capital | |
| 07.01.26 | AstraZeneca Overweight | Barclays Capital | |
| 07.01.26 | ABB (Asea Brown Boveri) Market-Perform | Bernstein Research | |
| 06.01.26 | ABB (Asea Brown Boveri) Underweight | Barclays Capital | |
| 06.01.26 | Hennes Mauritz (H M, H&M) Underperform | Bernstein Research | |
| 06.01.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 05.01.26 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.01.26 | Volvo (B) Overweight | JP Morgan Chase & Co. | |
| 05.01.26 | Ericsson (Telefon L.M.Ericsson) (B) Underperform | Bernstein Research | |
| 05.01.26 | Nokia Market-Perform | Bernstein Research | |
| 19.12.25 | Nokia Overweight | JP Morgan Chase & Co. | |
| 18.12.25 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 17.12.25 | ABB (Asea Brown Boveri) Sector Perform | RBC Capital Markets | |
| 16.12.25 | Volvo (B) Buy | UBS AG | |
| 16.12.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 16.12.25 | AstraZeneca Sell | Deutsche Bank AG | |
| 16.12.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 15.12.25 | Novo Nordisk Neutral | UBS AG | |
| 12.12.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 12.12.25 | Hennes Mauritz (H M, H&M) Underperform | Bernstein Research | |
| 12.12.25 | Novo Nordisk Neutral | UBS AG | |
| 11.12.25 | Hennes Mauritz (H M, H&M) Neutral | UBS AG | |
| 09.12.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 09.12.25 | Volvo (B) Hold | Deutsche Bank AG | |
| 08.12.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.12.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 05.12.25 | Novo Nordisk Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 04.12.25 | AstraZeneca Outperform | Bernstein Research | |
| 04.12.25 | Novo Nordisk Neutral | UBS AG | |
| 04.12.25 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. |
